This bill would add a class-wide listing to Schedule I of the Controlled Substances Act for a group of synthetic benzimidazole opioids commonly called nitazenes. It defines the covered chemicals by their shared 2-benzylbenzimidazole structure, specific types of substitutions, and the requirement that the substance acts as a mu-opioid receptor agonist. The bill lists example compounds (for example: etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, and others) and includes isomers, esters, ethers, and salts. Any nitazene that had been temporarily scheduled under section 201(h) would be treated as permanently scheduled on enactment. The bill also says that new research involving these substances still requires proper registration and scheduling compliance. The bill’s findings note that some nitazenes can be highly potent (sometimes exceeding fentanyl), that the DEA has already scheduled multiple compounds, that nitazenes have appeared in the illicit drug supply, and that class-wide permanent scheduling is intended to address new analogs and streamline enforcement. The bill references existing research pathways created by the HALT Fentanyl Act.
No publicly available information on budgetary costs or fiscal effects is included in the bill text.
The bill’s text states supporters believe class-wide scheduling is needed to preemptively address the creation of new nitazene analogs, to streamline enforcement, and to protect public health. The findings also note that some nitazenes are highly potent and that the DEA has already taken temporary or permanent scheduling actions for multiple compounds. The bill points to the HALT Fentanyl Act as maintaining research pathways for Schedule I substances.
No publicly available information on opposition arguments or views is included in the bill text.